Canpharma

Based in Oranienburg, Germany, Canpharma GmbH operates as a vertically integrated pharmaceutical company with a specific focus on cannabinoid-based products. The company holds Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) certifications, alongside licenses for the manufacturing, import, and trade of pharmaceuticals and controlled substances. Its business model covers the entire value chain, from research and development and cultivation to distribution and educational services for doctors, pharmacists, and patients. Canpharma aims to provide patients with access to a wide variety of medical cannabis treatments tailored to their individual needs.

The company was co-founded by Dr. Henrik Sprengel, who served as its CEO. Canpharma initiated its distribution activities in Germany in 2019. A significant milestone in the company's history was its acquisition by Health House International, an Australian pharmaceutical distributor, in a deal that closed in August 2021. This acquisition was intended to expand Health House's footprint into the European market while providing Canpharma with access to a broader supplier network. Following the acquisition, Dr. Sprengel was appointed as an executive director on Health House's board.

Canpharma's core business involves the importation and distribution of medical cannabis products, including both third-party and its own branded items. The company supplies pharmacies throughout Germany with high-quality medical cannabis flowers and oil extracts. A key operational strength is its focus on importing rare genetics from the United States to licensed nurseries in the European Union, ensuring a supply of high-quality flowers for its wholesale and retail partners in the EU and the UK. Furthermore, the company possesses a manufacturing license that allows it to repackage, brand, and release its own products. Canpharma also engages in the research and development of cannabis-based drugs and owns Kalapa Clinic in Spain, a consultancy focused on the medicinal use of cannabis. The company also offers services to breeders and geneticists, providing them with market access and coordination for the registration of clones, seeds, and tissue cultures.

Keywords: medical cannabis, cannabinoid products, pharmaceutical distribution, GMP certified, GDP certified, cannabis genetics, pharmaceutical manufacturing, controlled substances trade, European cannabis market, cannabis research and development, Kalapa Clinic, cannabinoid-based medicine, pharmaceutical import, pharmaceutical wholesale, cannabis oil extracts, cannabis flower, Oranienburg, Dr. Henrik Sprengel, Health House International, cannabis education